ORCHPHARMA · NSE
Orchid Pharma Limited
₹989.7
+3.30% (+₹31.65)
Prev. close
₹958.05
Volume
56,527
Delivery %
60.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including beta-lactam. It serves pharma companies, generic drug manufacturers, healthcare distributors, and institutional and government buyers. The company also exports its products to approximately 40 countries internationally. It has a strategic collaboration with Cipla for marketing across India. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Manish Dhanuka
Headquarters
Chennai
Employees
1,169
Website
orchidpharma.comExchange
View on NSE ↗Key stats
Market cap
₹5,019.67 Cr
P/E ratio (TTM)
303.6
EPS (TTM)
₹3.26
Beta (1Y · daily vs NIFTY 50)
1.12
Beta (5Y · monthly vs NIFTY 50)
1.78
Shares float
5.97 Cr
EPS · quarter ended Jun 2026
₹0.54
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹450.06 Cr | ₹559.56 Cr | ₹665.90 Cr | ₹819.37 Cr | ₹1,388.69 Cr | ₹1,217.17 Cr | |
| EBITDA | ₹65.00 Cr | ₹58.61 Cr | ₹142.26 Cr | ₹141.54 Cr | ₹176.33 Cr | ₹62.66 Cr |
| ₹-116.53 Cr | ₹-1.95 Cr | ₹46.32 Cr | ₹92.17 Cr | ₹135.07 Cr | ₹9.96 Cr | |
| Diluted EPS | ₹-28.55 | ₹-0.48 | ₹11.35 | ₹19.06 | ₹22.55 | ₹1.66 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,237.25 Cr | ₹1,110.56 Cr | ₹1,225.21 Cr | ₹1,553.87 Cr | ₹2,077.37 Cr | ₹2,258.43 Cr | |
| ₹452.74 Cr | ₹267.95 Cr | ₹331.35 Cr | ₹135.18 Cr | ₹153.71 Cr | ₹306.55 Cr | |
| Stockholders' equity | ₹652.91 Cr | ₹647.38 Cr | ₹688.65 Cr | ₹1,169.47 Cr | ₹1,553.93 Cr | ₹1,564.31 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹28.92 Cr | ₹88.95 Cr | ₹18.34 Cr | ₹125.99 Cr | ₹51.37 Cr | ₹125.64 Cr | |
| Investing cash flow | ₹94.57 Cr | ₹116.46 Cr | ₹-31.46 Cr | ₹-312.03 Cr | ₹-36.48 Cr | ₹-276.88 Cr |
| ₹85.17 Cr | ₹-216.80 Cr | ₹31.17 Cr | ₹167.04 Cr | ₹2.46 Cr | ₹137.14 Cr | |
| Capital expenditure | ₹-13.68 Cr | ₹-56.38 Cr | ₹-84.91 Cr | ₹-64.81 Cr | ₹-153.59 Cr | ₹-389.62 Cr |
| End cash position | ₹15.69 Cr | ₹4.31 Cr | ₹22.60 Cr | ₹3.60 Cr | ₹21.18 Cr | ₹7.07 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 22(3Q) | Jun 22–Mar 23(4Q) | Jun 23–Sep 23(3Q) | Dec 23–Jun 26(11Q) |
|---|---|---|---|---|
| Promoter | 90.00% | 89.96% | 72.40% | 69.84% |
| Public | 10.01% | 10.04% | 27.60% | 30.16% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Orchid Pharma Limited | ₹4,856.35 Cr | ₹958.05 | 293.7 | 3.10 | 0.6% | 0.20 | -12.4% | +33.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma sector stocks decline today, September 11: Sudeep Pharma falls 4.58%, Orchid Pharma down 3.56%, Alembic Pharma drops 1.43
Business Upturn · 8 days ago
Pharma sector stocks today, September 9: Orchid Pharma gains 3.28%, Biocon rises 1.73%; Indoco Remedies falls 2%
Business Upturn · 10 days ago